.jpg)
.png)
All
Visionary. Pioneer. Trailblazer. Inventor. Innovator. Boundary pusher. Those who push past what is for what can be. Pushing Boundaries, the theme for this edition of LipidSpin, was inspired and informed by our members and members of the lipid community as we collectively move past a time of... more
I have a 6 yo M seen in consultation recently for elevated LFTs, found on routine labs by PMD, AST/ALT 68/111, rest of chem 20 normal. TC 75, TG 127, HDL 13, LDL 37, TFTs normal, CBC shows slightly low Hb at 10.6. Asymptomatic, no signs on physical exam including no HSM, eating and growing well,... more
.v-center { display: flex; align-items: flex-start; justify-content: center; flex-grow: 1; width: 390px; padding: 10px } .flex-row { display: flex; flex-wrap: wrap; justify-content: center; } .... more
Background The random occurrence of heart attacks and strokes has always posed a medical challenge. Despite the association of circadian rhythm with increased incidence of cardiovascular events in the early morning hours, and triggers such as anger and emotional distress, the occurrence... more
The 21 Day Challenge The NLA is committed to diversity, equity, and inclusion as a core tenant of the organization. The 21 Day Challenge is sponsored by the NLA Diversity, Equity & Inclusion Task Force. The DEI Task Force challenges you to review all 21 content items and... more
Cardiovascular disease (CVD) remains the leading cause of mortality in those > 75 years of age.1 In the United States, an estimated 84 million people have CVD, with approximately 50% of these Americans being ≥ 60 years old.2 The prevalence of CVD increases with age, from 15% in men and 9% in... more
Despite the fact that high LDL-C (bad cholesterol) is a critical heart health factor for adults, 71 percent of Americans surveyed (n=2,033) are not sure of or do not recall their LDL-C (bad cholesterol) levels, according to the initial results from the Cholesterol Counts Poll released today... more
Regeneron Pharmaceuticals, Inc. today announced that the New England Journal of Medicine (NEJM) published positive results from the Phase 3 trial of evinacumab in 65 patients with homozygous familial hypercholesterolemia (HoFH). Evinacumab is an investigational medicine that... more